{"id":11446,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2026-02-04T09:48:03","modified_gmt":"2026-02-04T09:48:03","slug":"hipertermija-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-qol\/","title":{"rendered":"Hipertermijos poveikis gyvenimo kokybei (QoL): skausmo mal\u0161inimas, nuovargio ma\u017einimas ir adjuvantin\u0117 imunologin\u0117 nauda"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-qol\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-qol\/\",\n      \"name\": \"Hipertermija ir gyvenimo kokyb\u0117 (QoL) onkologijoje | Andromedic\",\n      \"description\": \"Mokslin\u0117 analiz\u0117 apie tai, kaip hipertermija gerina gyvenimo kokyb\u0119 (QoL) mal\u0161indama skausm\u0105 (A1 lygio \u012frodymai) ir ma\u017eindama nuovarg\u012f.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"lt\",\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\" }\n      ]\n    },\n    \/* 1. PAGRINDINIS MOKSLINIS STRAIPSNIS *\/\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-qol\/#article\",\n      \"headline\": \"Hipertermijos poveikis gyvenimo kokybei (QoL): skausmo mal\u0161inimas ir funkcin\u0117 nauda\",\n      \"author\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-veronica-iatan\/\" },\n      \"editor\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\" },\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"keywords\": [\"Gyvenimo kokyb\u0117\", \"Skausmo valdymas\", \"A1 lygio \u012frodymai\", \"Paliatyvi pagalba\", \"EORTC QLQ-C30\"],\n      \"abstract\": \"III faz\u0117s RCT tyrim\u0173 ap\u017evalga, \u012frodanti, kad lokoregionin\u0117 RF hipertermija reik\u0161mingai padidina visi\u0161k\u0105 skausmo atsak\u0105 (CR) esant kaul\u0173 metastaz\u0117ms ir pagerina fizinio bei emocinio funkcionavimo balus.\",\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\" }\n      ]\n    },\n    \/* 2. III FAZ\u0116S KLINIKINIS TYRIMAS - CHI MS IR KT. *\/\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\",\n      \"name\": \"III faz\u0117s RCT: RT prie\u0161 RT + hipertermij\u0105 mal\u0161inant skausmingas kaul\u0173 metastazes\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"Visi\u0161ko skausmo atsako rodiklis (CR) po 3 m\u0117nesi\u0173 pager\u0117jo nuo 7,1 % (tik RT) iki 37,9 % (RT + hipertermija).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/\"\n    },\n    \/* 3. III FAZ\u0116S KLINIKINIS TYRIMAS - SAHINBAS\/FAGHIHI IR KT. *\/\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\",\n      \"name\": \"III faz\u0117s klinikinis tyrimas: Termin\u0117 terapija prie\u0161 EBRT esant kaul\u0173 metastaz\u0117ms\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"CR rodiklis po 2 m\u0117nesi\u0173: 47,4 % (kombinuota terapija) prie\u0161 5,3 % (tik radioterapija). Mediana iki skausmo mal\u0161inimo: 10 dien\u0173.\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/\"\n    },\n    \/* 4. \u012eRENGINYS *\/\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"sku\": \"HYDEEP-600WM-QOL\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/07\/advanced-modulated-RF-hyperthermia-device-Andromedic-HY-DEEP-600WM-local-oncologic-hyperthermia.jpg\",\n      \"description\": \"Profesionalus 13,56 MHz moduliuotos RF hipertermijos \u012frenginys. Sukurtas lokoregionin\u0117s termin\u0117s terapijos protokolams, klini\u0161kai \u012frodytiems gerinti QoL ir ma\u017einti v\u0117\u017eio sukelt\u0105 skausm\u0105.\",\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/lt\/kontaktai\/\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\"\n      }\n    },\n    \/* 5. MEDICININ\u0116 INDIKACIJA *\/\n    {\n      \"@type\": \"MedicalIndication\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\",\n      \"name\": \"V\u0117\u017eio skausmo mal\u0161inimas ir nuovargio kontrol\u0117\",\n      \"description\": \"Adjuvantin\u0117 hipertermija indikuotina geresnei simptom\u0173 kontrolei, fiziniam ir emociniam funkcionavimui palaikyti paliatyvios ir kuratyvios terapijos metu.\",\n      \"guideline\": \"A1 lygio \u012frodymai (Chi MS ir kt. 2017, Sahinbas 2024)\"\n    },\n    \/* 6. ASMENYS *\/\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"jobTitle\": \"SRHO bendra\u012fk\u016br\u0117ja, medicinos ekspert\u0117\",\n      \"affiliation\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#srho\" },\n      \"address\": {\n        \"@type\": \"PostalAddress\",\n        \"streetAddress\": \"Strada Stadionului 25G\",\n        \"addressLocality\": \"Clinceni\",\n        \"postalCode\": \"077060\",\n        \"addressCountry\": \"RO\"\n      }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\",\n      \"name\": \"Cristian Gologan\",\n      \"jobTitle\": \"\u201ePremium Wellness Distrib SRL\u201c vadovas, SRHO vadovas ir bendra\u012fk\u016br\u0117jis\"\n    }\n  ]\n}\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoritetas ir patirtis (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pareng\u0117 <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/lt\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, medicinos moksl\u0173 daktar\u0117, ir <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan, magistras<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, \u201eAndromedichyperthermia\u201c<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermijos poveikis gyvenimo kokybei (QoL): skausmo mal\u0161inimas, nuovargio ma\u017einimas ir adjuvantin\u0117 imunologin\u0117 nauda<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160iuolaikin\u0117je onkologijoje v\u0117\u017eio gydymas siekia optimalios pusiausvyros tarp <a href=\"https:\/\/andromedichyperthermia.com\/lt\/hipertermija-pacientu-isgyvenamumas\/\">i\u0161gyvenamumo (OS\/DFS)<\/a> ir <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*gyvenimo kokyb\u0117s (QoL)*.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija (HT) yra unikalus adjuvantinis metodas, kurio poveikis gyvenimo kokyb\u0117s gerinimui \u012fvairiais lygmenimis \u2013 simptom\u0173 kontrol\u0117s, bendros funkcin\u0117s b\u016bkl\u0117s ir puikaus saugumo profilio \u2013 buvo \u012frodytas svarbiais klinikiniais tyrimais (<\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/lt\/hipertermijos-iii-fazes-tyrimu\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III faz\u0117s RCT<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">).<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Pagrindin\u0117 paliatyvi nauda: skausmo kontrol\u0117 (A1 lygio \u012frodymai i\u0161 III faz\u0117s klinikini\u0173 tyrim\u0173)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastazinis kaul\u0173 skausmas \u017eenkliai prastina gyvenimo kokyb\u0119. Lokoregionin\u0117 RF hipertermija, derinama su radioterapija (RT), u\u017etikrina prana\u0161esn\u0119 paliatyvi\u0105 kontrol\u0119, remiantis <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Chi MS ir kt. paskelbtu III faz\u0117s tyrimu<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (2017 m.) [1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL rodiklis \/ Skausmo ma\u017e\u0117jimas<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (HT)<\/span><\/span><\/th>\n<th>Poveikis QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Visi\u0161ko atsako rodiklis (CR) po 3 m\u0117n.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulinis skausmo balas)<\/span><\/span><\/td>\n<td>*7,1 %*<\/td>\n<td>*37,9 %*<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*533 % didesn\u0117* visi\u0161ko skausmo mal\u0161inimo tikimyb\u0117.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Skausmo mal\u0161inimo trukm\u0117<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: *55 dienos \/ 7,9 savait\u0117s*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: *Nepasiekta per 24 savaites*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palengv\u0117jimo trukm\u0117 *patrigub\u0117ja*, ma\u017einant priklausomyb\u0119 nuo vaist\u0173 nuo skausmo.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 m. <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sahinbas ir kolegos paskelb\u0117 III faz\u0117s tyrim\u0105<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> d\u0117l kaul\u0173 metastazi\u0173 sukelto skausmo, daugiausia sergant kr\u016bties ir prostatos v\u0117\u017eiu, taikant WBHT wIRA hipertermij\u0105 kartu su RT [2].<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Remiantis \u0161iuo tyrimu, tik radioterapijos (RT) grup\u0117s pacientai jaut\u0117 intensyviausi\u0105 skausm\u0105. Tyrimas baigtas \u012ftraukus 61 pacient\u0105, pra\u0117jus 5 metams nuo pirmojo \u012ftraukimo (2016 m. balandis \u2013 2021 m. vasaris). Galiausiai, CR rodiklis RT + WBH grup\u0117je parod\u0117 reik\u0161mingiausi\u0105 skirtum\u0105 lyginant su RT grupe \u2013 atitinkamai 47,4 % ir 5,3 % per 2 m\u0117nesius po gydymo (P vert\u0117 &lt; 0,05). Laikas iki visi\u0161ko skausmo mal\u0161inimo RT + WBH grup\u0117je buvo 10 dien\u0173, tuo tarpu RT grup\u0117je \u0161is galutinis ta\u0161kas nebuvo pasiektas. Skausmo progresavimas arba ligos stabilumas buvo pasteb\u0117tas pusei RT grup\u0117s pacient\u0173 per 4 savaites po gydymo. Ta\u010diau RT + WBHT pacient\u0173 grup\u0117je \u0161is balas buvo artimas nuliui per du m\u0117nesius po gydymo.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I\u0161vados: <\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH kartu su RT parod\u0117 reik\u0161mingai geresn\u012f skausmo mal\u0161inim\u0105 ir trumpesn\u012f atsako laik\u0105, lyginant su vien tik RT taikymu pacientams, turintiems metastazini\u0173 kaul\u0173 pa\u017eeidim\u0173.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL rodiklis \/ Skausmo ma\u017e\u0117jimas<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Poveikis QoL<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Visi\u0161ko atsako rodiklis (CR) po 2 m\u0117nesi\u0173<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nulinis skausmo balas)<\/span><\/span><\/td>\n<td>*5,3 %*<\/td>\n<td>*47,4 %*<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % padid\u0117jimas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * visi\u0161ko skausmo pa\u0161alinimo tikimyb\u0117je.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Laikas iki visi\u0161ko skausmo mal\u0161inimo<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">nepasiekta<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dien\u0173<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">\u201ereik\u0161minga ir greita\u201c<\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"> nauda<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Skausmo mal\u0161inimo trukm\u0117<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: *28 dienos \/ 4 savait\u0117s* pusei pacient\u0173<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mediana: *Nepasiekta per 24 savaites*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palengv\u0117jimo trukm\u0117 * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">padid\u0117ja \u0161e\u0161is kartus<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, ma\u017einant priklausomyb\u0119 nuo vaist\u0173.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Funkcin\u0117s b\u016bkl\u0117s gerinimas ir nuovargio ma\u017einimas<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT nauda gyvenimo kokybei yra tiesiogiai matuojama standartizuotais klausimynais (EORTC QLQ-C30), rodan\u010diais bendros b\u016bkl\u0117s (fizin\u0117s funkcijos, nuovargio ir nerimo) pager\u0117jim\u0105:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Reik\u0161mingai pager\u0117jusi QoL (moduliuota RF hipertermija mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomizuotas klinikinis moduliuotos RF hipertermijos (mEHT) tyrimas sergant gimdos kaklelio v\u0117\u017eiu parod\u0117 *reik\u0161ming\u0105 ilgalaiki\u0173 QoL bal\u0173 pager\u0117jim\u0105* \u2013 pacientai nurod\u0117 geresnius *fizinio ir emocinio funkcionavimo* skali\u0173 \u012fvertinimus [3].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nuovargio kontrol\u0117 ir imunomoduliacija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> viso k\u016bno hipertermija (WBHT) ir HT apskritai teigiamai veikia *l\u0117tinio nuovargio sindrom\u0105 (CRF)*, moduliuodama u\u017edegiminius citokinus (IL-6, TNF-alfa). HT taip pat padeda ilg\u0105 laik\u0105 i\u0161laikyti ir pagerinti *fizinio bei emocinio funkcionavimo* skali\u0173 balus [4].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Greitas emocinis atsigavimas (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> po dideli\u0173 chirurgini\u0173 proced\u016br\u0173, apiman\u010di\u0173 HT (HIPEC), emocin\u0117 gyvenimo kokyb\u0117 linkusi *greitai ger\u0117ti*, pradedant jau nuo *3 m\u0117nesio* po operacijos, da\u017enai vir\u0161ydama pradin\u012f lyg\u012f [5].<\/span><\/span><\/li>\n<\/ul>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Ilgalaik\u0117s gyvenimo kokyb\u0117s naudos \u012ftvirtinimas<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Realaus pasaulio duomenys ir klinikiniai tyrimai sergant pa\u017eengusiu v\u0117\u017eiu patvirtina hipertermijos vaidmen\u012f stabilizuojant ir gerinant ilgalaik\u0119 QoL:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Gydomasis poveikis po 12 m\u0117nesi\u0173:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> i\u0161sami pacient\u0173, gydyt\u0173 radikaliais metodais (RCT + HT), analiz\u0117 parod\u0117 reik\u0161ming\u0105 pager\u0117jim\u0105, i\u0161likus\u012f per 12 m\u0117nesi\u0173 laikotarp\u012f, vertinant emocin\u012f, socialin\u012f funkcionavim\u0105 bei nemigos (SL) skales, lyginant su EORTC onkologine referencine populiacija [10].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Paliatyvi nauda:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> paliatyviame kontekste HT papildymas prie standartinio gydymo l\u0117m\u0117 klini\u0161kai reik\u0161ming\u0105 skausmo (PA) suma\u017e\u0117jim\u0105 ir finansini\u0173 sunkum\u0173 (FI) ma\u017einim\u0105 pra\u0117jus 3 m\u0117nesiams po gydymo, prisidedant prie geresn\u0117s bendros paciento b\u016bkl\u0117s [10].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pager\u0117jusi QoL esant pa\u017eengusiai ligai (kolorektalinis v\u0117\u017eys):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> tyrime, vertinan\u010diame chemoterapij\u0105 kartu su auk\u0161to da\u017enio hipertermija tarpinio ir pa\u017eengusio stadijos kolorektalinio v\u0117\u017eio pacientams, kombinuoto gydymo grup\u0117 parod\u0117 reik\u0161mingai auk\u0161tesnius (pager\u0117jusius) QoL balus po 4 gydymo cikl\u0173, \u012frodant, kad HT efektyviai gerina gyvenimo kokyb\u0119 kartu su terapiniu poveikiu, i\u0161laikant didesn\u012f saugum\u0105 [11].<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvantin\u0117 biologin\u0117 nauda ir auk\u0161tesnis terapinis indeksas<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksimaliai padidina gydymo letalum\u0105 (poveik\u012f v\u0117\u017eiui) be reik\u0161mingo sunkaus toksi\u0161kumo (3-4 laipsnio) rizikos padid\u0117jimo, taip i\u0161laikant auk\u0161t\u0105 terapin\u012f indeks\u0105:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Patvirtintas saugumas (III faz\u0117s klinikiniai tyrimai):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> gimdos kaklelio v\u0117\u017eio meta-analiz\u0117s rodo *reik\u0161mingo skirtumo nebuvim\u0105* tarp \u016bminio ar v\u0117lyvojo toksi\u0161kumo (RR toksi\u0161kumas 1,01) [6]. Saugumo profilis i\u0161laikomas tiesiosios \u017earnos [7] ir kasos v\u0117\u017eio tyrimuose [8].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Organ\u0173 i\u0161saugojimas:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> sergant tiesiosios \u017earnos v\u0117\u017eiu, HT papildymas neoadjuvantin\u0117je chemoradioterapijoje padidina 5 met\u0173 i\u0161gyvenamum\u0105 be kolostomos (CFS) nuo 69,0 % iki *87,7 %*, kas yra did\u017eiul\u0117 funkcin\u0117 QoL nauda [7].<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*<strong>Abskopinis (vakcin\u0105 primenantis) efektas:<\/strong>* HT sukelia *imunogenin\u0119 l\u0105steli\u0173 \u017e\u016bt\u012f*, i\u0161skirdama \u0161iluminio \u0161oko baltymus (HSP), kurie aktyvuoja citotoksinius CD8+ T l\u0105steles. \u0160is sisteminis imunologinis \u017eingsnis prisideda prie likutin\u0117s ligos kontrol\u0117s ir yra esmin\u0117 adjuvantin\u0117 nauda [9].<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I\u0161vada: \u012f pacient\u0105 orientuota terapija<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermijos integravimas \u012f onkologin\u012f protokol\u0105 yra pa\u017eangi, \u012frodymais pagr\u012fsta strategija, kuri ne tik gerina i\u0161gyvenamum\u0105, bet ir u\u017etikrina stipri\u0105 simptom\u0173 kontrol\u0119 bei palaiko gyvenimo kokyb\u0119. Skausmo mal\u0161inimas, nuovargio kontrol\u0117 ir puikus saugumo profilis daro HT esminiu holistin\u0117s onkologinio paciento prie\u017ei\u016bros elementu.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvie\u010diame konsultuotis su m\u016bs\u0173 ekspertais d\u0117l hipertermijos integravimo \u012f j\u016bs\u0173 protokol\u0105, siekiant maksimalaus efektyvumo ir gyvenimo kokyb\u0117s.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT u\u017etikrinimas:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0161is turinys pagr\u012fstas paskelbtais duomenimis i\u0161 III faz\u0117s randomizuot\u0173 ir perspektyvini\u0173 klinikini\u0173 tyrim\u0173, naudojant standartinius gyvenimo kokyb\u0117s matavimo instrumentus (EORTC QLQ-C30). Visos nuorodos yra integruotos su tiesiogin\u0117mis nuorodomis \u012f \u0161altini\u0173 publikacijas.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nuorodos:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clinical Rheumatology (2008).<\/li>\n<li>Ryan B. Morgan, Sandy Tun, Oliver S. Eng. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S. et al. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol 195, 607\u2013614 (2019).<\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226.<\/li>\n<li>Baronzio, G. F., et al. (2020). Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Frontiers in Oncology.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritetas ir patirtis (EEAT): Pareng\u0117 dr. Veronica Iatan, medicinos moksl\u0173 daktar\u0117, ir Cristian Gologan, magistras, \u201eAndromedichyperthermia\u201c Hipertermijos poveikis gyvenimo kokybei (QoL): skausmo mal\u0161inimas, nuovargio ma\u017einimas ir adjuvantin\u0117 imunologin\u0117 nauda \u0160iuolaikin\u0117je onkologijoje v\u0117\u017eio gydymas siekia optimalios pusiausvyros tarp i\u0161gyvenamumo (OS\/DFS) ir *gyvenimo kokyb\u0117s (QoL)*. Hipertermija (HT) yra unikalus adjuvantinis metodas, kurio poveikis gyvenimo kokyb\u0117s gerinimui \u012fvairiais&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[173,959,38],"tags":[960,961,962,373,337,963,964,965,966],"class_list":["post-11446","post","type-post","status-publish","format-standard","hentry","category-news-lt","category-studii-clinice-lt","category-uncategorized-lt","tag-calitatea-vietii-lt","tag-durere-lt","tag-hipertermie-oncologica-lt","tag-hipertermija-lt","tag-oncology-lt","tag-pain-lt","tag-phase-iii-trial-lt","tag-qol-lt","tag-studii-faza-iii-lt"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/11446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/comments?post=11446"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/posts\/11446\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/media?parent=11446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/categories?post=11446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lt\/wp-json\/wp\/v2\/tags?post=11446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}